Renaissance Capital logo

Stealth BioTherapeutics Priced, Nasdaq: MITO

Phase 3 biotech focused on rare diseases caused by mitochondrial dysfunction.

Industry: Health Care

Latest Trade: $11.46 0.00 (0.0%)

First Day Return: -0.8%

Return from IPO: -4.5%

Industry: Health Care

We are a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases, collectively known as primary mitochondrial diseases, and are also involved in many common age-related diseases. We believe our lead product candidate, elamipretide, has the potential to treat both rare genetic and common age-related mitochondrial diseases. Our mission is to be the leader in mitochondrial medicine, and we have assembled a highly experienced management team, board of directors and group of scientific advisors to help us achieve this mission.
more less
IPO News for Stealth BioTherapeutics
more
IPO Data
IPO File Date 12/28/2018
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.5
Deal Size ($mm) $78
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 02/14/2019
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 6.5
Deal Size ($mm) $78
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Newton, MA
Founded 2006
Employees 57
Website www.stealthbt.com